VANCOUVER, British Columbia, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CNSX:IPOT.CN) (XFRA:A2PT0E) (OTC:ISCNF) (the “Company” or “Isracann”) a biosciences company focused on researching and developing innovative health solutions in conjunction with its advanced stage activities aimed at becoming a premier low-cost, high-quality cannabis producer/distributor is pleased to announce that on February 16, 2022, it entered into a binding LOI to acquire Praesidio Health Inc. of Canada (“Praesidio”).
UPDATE - Isracann Signs LOI to Acquire Natural Health Medicine Developer
Globe Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/Intel%20Corp_%20logo%20on%20mobile%20phone-by%20Piotr%20Swat%20via%20Shutterstock.jpg)
/Nvidia%20logo%20by%20Konstantin%20Savusia%20via%20Shutterstock.jpg)
/Alphabet%20(Google)%20Image%20by%20Markus%20Mainka%20via%20Shutterstock.jpg)
/An%20image%20of%20a%20Tesla%20humanoid%20robot%20in%20front%20of%20the%20company%20logo%20Around%20the%20World%20Photos%20via%20Shutterstock.jpg)